Treatment progress of chemotherapy induced thrombocytopenia / 实用肿瘤学杂志
Practical Oncology Journal
;
(6): 184-188, 2016.
Artículo
en Chino
| WPRIM
| ID: wpr-499260
ABSTRACT
Chemotherapy induced thrombocytopenia( CIT) is a major dose-limiting hematologic toxicity with cancer patients.Aside from bleeding risk, thrombocytopenia limits chemotherapy doses and frequencies. While platelet transfusion is remain the elementary method for CIT,administration of platelet growth factors,such as recombinant human interleukin-11(rhIL-11),recombinant human thrombopoietin(rhTPO)and thrombopoie-tin receptor agonist(TPO-RA),are convenient and effective platelet-support strategies for patients receiving myelosuppressive chemotherapy.In addition,other cytokines and proximal splenic artery embolization( PSAE) are expected to be new clinical therapies.In this review,we summarize the existing data and approaches in the treat-ment progress of CIT.
Texto completo:
Disponible
Índice:
WPRIM (Pacífico Occidental)
Idioma:
Chino
Revista:
Practical Oncology Journal
Año:
2016
Tipo del documento:
Artículo
Similares
MEDLINE
...
LILACS
LIS